Endocrine Pharmacology Practice Questions

Q: Which of the following drugs is contraindicated in liver disease?

Vildagliptin. **Explanation:** The correct answer is **Vildagliptin**. **Why Vildagliptin is the correct answer:** Vildagliptin is unique among the Dipeptidyl Peptidase-4 (DPP-4) inhibitors because it has been associated with a risk of **hepatic dysfunction** and elevations in serum transaminases (ALT/AST). Due to this potential for hepatotoxicity, it is **contraindicated** in patients with pre-existing hepatic impairment, including those with ALT or AST levels >3 times the upper limit of normal (ULN) prior to treatment. Clinical guidelines recommend monitoring Liver Function Tests (LFTs) at three-month intervals during the first year of therapy with Vildagliptin. **Analysis of Incorrect Options:** * **Sitagliptin:** Primarily excreted unchanged by the kidneys. It does not require dose adjustment in mild-to-moderate hepatic impairment and is not contraindicated in liver disease. * **Saxagliptin:** Metabolized by the liver (CYP3A4/5), but it is considered safe for use in patients with hepatic impairment. Dose adjustments are typically required for renal impairment, not liver disease. * **Alogliptin:** Primarily excreted renally. No dose adjustment is necessary for patients with hepatic impairment, and it does not carry the same hepatotoxicity warnings as Vildagliptin. **High-Yield Clinical Pearls for NEET-PG:** * **Renal Adjustment:** All DPP-4 inhibitors except **Linagliptin** require dose adjustment in renal failure. Linagliptin is primarily excreted via the bile/feces, making it the drug of choice for diabetic patients with CKD. * **Heart Failure Warning:** Saxagliptin and Alogliptin have been linked to an increased risk of hospitalization for heart failure. * **Weight Neutrality:** Unlike Sulfonylureas or Insulin, DPP-4 inhibitors are weight-neutral and have a low risk of hypoglycemia. * **Adverse Effect:** Nasopharyngitis is the most common side effect reported with this class.

Q: Medical adrenalectomy is achieved with which of the following medications?

Aminoglutethimide. **Explanation:** **Medical adrenalectomy** refers to the pharmacological inhibition of adrenal steroid synthesis, effectively mimicking a surgical adrenalectomy. **Correct Option: A. Aminoglutethimide** Aminoglutethimide is the drug of choice for medical adrenalectomy. It acts by inhibiting the enzyme **Desmolase** (CYP11A1), which converts cholesterol to pregnenolone. This is the "rate-limiting step" in the synthesis of all adrenal steroids (glucocorticoids, mineralocorticoids, and androgens). It was historically used in the treatment of Cushing’s syndrome and hormone-dependent breast cancer. **Why the other options are incorrect:** * **B. Methotrexate:** A folate antagonist (inhibits dihydrofolate reductase) used as a disease-modifying antirheumatic drug (DMARD) and in cancer chemotherapy. * **C. Melphalan:** An alkylating agent (nitrogen mustard derivative) primarily used in the treatment of multiple myeloma. * **D. Flutamide:** A non-steroidal competitive antagonist at androgen receptors, used primarily in the management of prostate cancer, not for inhibiting adrenal steroid synthesis. **High-Yield Clinical Pearls for NEET-PG:** * **Other Adrenal Steroid Inhibitors:** * **Ketoconazole:** Inhibits 17α-hydroxylase and 11β-hydroxylase; it is the most commonly used drug for Cushing’s syndrome today. * **Metyrapone:** Specifically inhibits **11β-hydroxylase**, blocking cortisol synthesis (used in diagnostic testing of the HPA axis). * **Mitotane:** An adrenolytic drug that causes selective destruction of adrenocortical cells (used in adrenal carcinoma). * **Aminoglutethimide** also inhibits the **Aromatase** enzyme, preventing the peripheral conversion of androgens to estrogens.

Q: What is the drug of choice for lithium-induced diabetes insipidus?

Amiloride. **Explanation:** **Mechanism of the Correct Answer (Amiloride):** Lithium-induced Nephrogenic Diabetes Insipidus (NDI) occurs because lithium enters the principal cells of the collecting duct through **ENaC (Epithelial Sodium Channels)**. Once inside, lithium inhibits adenylate cyclase, interfering with ADH-mediated water reabsorption. **Amiloride** is the drug of choice because it is a potassium-sparing diuretic that **blocks ENaC**. By blocking these channels, amiloride prevents lithium from entering the tubular cells, thereby reversing the interference with ADH and restoring the kidney's concentrating ability. **Analysis of Incorrect Options:** * **Conivaptan:** This is a vasopressin receptor antagonist (Vaptan). It is used to treat SIADH (hyponatremia) by promoting water excretion; it would worsen the polyuria in diabetes insipidus. * **Indapamide:** While Thiazide-like diuretics (and Thiazides) are used to treat other forms of NDI by inducing mild volume depletion, they are not the specific treatment for lithium-induced cases because they do not address the lithium entry mechanism. * **Vasopressin:** In NDI, the kidneys are resistant to ADH. Therefore, administering exogenous vasopressin (or Desmopressin) will not improve the condition. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice for Central DI:** Desmopressin (dDAVP). * **Drug of Choice for General NDI:** Thiazides (e.g., Hydrochlorothiazide). * **Lithium Toxicity:** Lithium has a narrow therapeutic index (0.6–1.2 mEq/L). Apart from NDI, it commonly causes hypothyroidism and Ebstein's anomaly (teratogenicity). * **Paradoxical Effect:** Thiazides treat NDI by causing proximal tubule sodium/water reabsorption, reducing the volume delivered to the distal nephron.

Q: All of the following are true about sitagliptin EXCEPT:

It is always given with insulin.. ### Explanation **Sitagliptin** is a competitive, reversible inhibitor of the enzyme **Dipeptidyl Peptidase-4 (DPP-4)**. This enzyme is responsible for the degradation of incretin hormones like GLP-1 and GIP. By inhibiting DPP-4, sitagliptin increases the levels of active incretins, which stimulate insulin release and inhibit glucagon secretion in a glucose-dependent manner. #### Why Option A is the Correct Answer (The False Statement) Sitagliptin is primarily used as **monotherapy** or in combination with other oral hypoglycemic agents (like Metformin or Pioglitazone) for Type 2 Diabetes Mellitus (T2DM). It is **not** always given with insulin; in fact, it is often used to delay the need for insulin therapy. Furthermore, it is not indicated for Type 1 Diabetes, where insulin is mandatory. #### Analysis of Other Options: * **Option B:** Incretins are secreted in response to food intake. Therefore, DPP-4 inhibitors primarily enhance the insulin response to meals, making them highly effective at reducing **postprandial blood sugar (PPBS)** with a minimal risk of hypoglycemia. * **Option C:** Sitagliptin is generally **weight-neutral** and has a low risk of hypoglycemia (unlike sulfonylureas) and no risk of edema or bone loss (unlike TZDs). Common side effects are mild, such as nasopharyngitis or upper respiratory tract infections. * **Option D:** Clinical trials consistently show that sitagliptin effectively lowers **HbA1c** by approximately 0.5–0.8% when used as monotherapy or in combination. #### NEET-PG High-Yield Pearls: * **Mechanism:** Glucose-dependent insulin secretion (low risk of hypoglycemia). * **Weight Effect:** Weight neutral (unlike GLP-1 agonists which cause weight loss). * **Renal Adjustment:** Requires dose adjustment in renal failure (except **Linagliptin**, which is primarily excreted via bile). * **Rare Serious Side Effect:** Acute pancreatitis (monitor for persistent severe abdominal pain).

Q: Which of the following characteristics makes metformin a preferred biguanide compared to phenformin?

It is less liable to cause lactic acidosis. **Explanation:** **1. Why Option B is Correct:** The primary reason metformin replaced phenformin in clinical practice is its significantly lower risk of **lactic acidosis**. Phenformin was withdrawn globally in the 1970s because it has a high affinity for mitochondrial membranes, where it strongly inhibits the mitochondrial respiratory chain (Complex I). This leads to excessive anaerobic glycolysis and a massive buildup of lactate. Metformin, being less lipophilic, has a much weaker effect on mitochondrial respiration at therapeutic doses, making it a safer profile for glycemic control. **2. Why Other Options are Incorrect:** * **Option A:** Phenformin is actually **more potent** than metformin on a milligram-to-milligram basis, but its higher potency is associated with its increased toxicity. * **Option C:** Both metformin and phenformin can interfere with **Vitamin B12 absorption** in the terminal ileum. Long-term metformin use is a well-known cause of B12 deficiency, requiring periodic monitoring. * **Option D:** Metformin is primarily excreted unchanged by the kidneys. Therefore, it is **contraindicated** in patients with significant renal impairment (typically eGFR <30 mL/min) due to the increased risk of accumulation and subsequent lactic acidosis. **3. Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Metformin activates **AMP-activated protein kinase (AMPK)**, leading to decreased hepatic gluconeogenesis and improved peripheral insulin sensitivity. * **Weight Neutrality:** Unlike sulfonylureas or insulin, metformin does not cause weight gain; it is often weight-neutral or promotes modest weight loss. * **First-line Status:** It is the drug of choice for Type 2 Diabetes Mellitus, especially in obese patients. * **Side Effects:** The most common side effects are GI-related (diarrhea, abdominal cramps). The most serious (though rare) is lactic acidosis.

Q: Which drug's action requires the presence of insulin to produce its therapeutic effect?

Pioglitazone. **Explanation:** The correct answer is **Pioglitazone**. **1. Why Pioglitazone is correct:** Pioglitazone belongs to the **Thiazolidinedione (TZD)** class. Its primary mechanism of action is as a selective agonist for the nuclear receptor **PPAR-γ** (Peroxisome Proliferator-Activated Receptor gamma). Activation of this receptor increases the transcription of genes involved in glucose and lipid metabolism, effectively acting as an **insulin sensitizer**. Because Pioglitazone works by enhancing the body's response to insulin (reducing insulin resistance in muscle, fat, and liver), it is physiologically dependent on the presence of either endogenous or exogenous insulin to exert its glucose-lowering effect. **2. Analysis of Incorrect Options:** * **A. Glibenclamide (Sulfonylurea):** These are insulin secretagogues. They work by closing ATP-sensitive K+ channels in pancreatic beta cells, causing depolarization and insulin release. They require functional beta cells, but not the presence of insulin itself, to act. * **B. Nateglinide (Meglitinide):** Similar to sulfonylureas, these are short-acting secretagogues that stimulate the release of insulin from the pancreas. * **C. Empagliflozin (SGLT-2 Inhibitor):** This drug acts on the proximal convoluted tubule of the kidney to inhibit glucose reabsorption. Its mechanism is entirely **insulin-independent**, making it effective even in states of absolute insulin deficiency. **3. NEET-PG High-Yield Pearls:** * **TZDs and Weight:** Unlike many other antidiabetics, TZDs can cause weight gain (due to fluid retention and adipocyte differentiation). * **Contraindication:** Avoid TZDs in patients with NYHA Class III/IV Heart Failure due to the risk of fluid overload. * **Metformin vs. Pioglitazone:** Both are sensitizers, but Metformin primarily acts on the liver (AMPK activation), while TZDs primarily act on peripheral tissues (PPAR-γ).

Q: All of the following drugs can be used in the treatment of postmenopausal osteoporosis EXCEPT:

Thyroxine. ### Explanation **Correct Answer: D. Thyroxine** **Why Thyroxine is the Correct Answer:** Thyroxine is not a treatment for osteoporosis; in fact, **excessive thyroxine is a known risk factor for secondary osteoporosis.** High levels of thyroid hormone (hyperthyroidism or over-replacement therapy) increase bone turnover by stimulating osteoclastic activity more than osteoblastic activity. This leads to a shortened remodeling cycle and a net loss of bone mineral density (BMD). Therefore, it is contraindicated as a treatment and must be monitored carefully in osteoporotic patients. **Analysis of Other Options:** * **A. Alendronate:** A nitrogen-containing **Bisphosphonate**. It is the first-line treatment for postmenopausal osteoporosis. It works by inhibiting osteoclast-mediated bone resorption. * **B. Teriparatide:** A recombinant human **Parathyroid Hormone (rhPTH 1-34)**. It is an anabolic agent that stimulates new bone formation (osteoblastic activity) when given in intermittent pulses. * **C. Calcium:** Essential supplementation in osteoporosis management. It ensures adequate mineralization of the bone matrix and suppresses compensatory PTH secretion which would otherwise cause bone resorption. **NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC):** Bisphosphonates (e.g., Alendronate, Zoledronic acid) are the first-line agents for most patients. * **Anabolic vs. Antiresorptive:** Teriparatide and Romosozumab are **anabolic** (build bone), while Bisphosphonates, Denosumab, and SERMs are **antiresorptive** (prevent breakdown). * **Denosumab:** A monoclonal antibody against **RANKL**, administered subcutaneously every 6 months. * **Side Effect Note:** Long-term bisphosphonate use is associated with **Atypical Femur Fractures** and **Osteonecrosis of the Jaw (ONJ)**.

Question 1

Which of the following drugs is contraindicated in liver disease?

Accepted Answer

Vildagliptin

Answer

Sitagliptin

Answer

Saxagliptin

Answer

Alogliptin

Question 2

Medical adrenalectomy is achieved with which of the following medications?

Accepted Answer

Aminoglutethimide

Answer

Methotrexate

Answer

Melphalan

Answer

Flutamide

Question 3

What is the drug of choice for lithium-induced diabetes insipidus?

Accepted Answer

Amiloride

Answer

Conivaptan

Answer

Indapamide

Answer

Vasopressin

Question 4

All of the following are true about sitagliptin EXCEPT:

Accepted Answer

It is always given with insulin.

Answer

It preferentially reduces postprandial blood sugar.

Answer

It has fewer side effects compared to other antidiabetic agents.

Answer

It lowers HbA1c.

Question 5

Which of the following statements regarding Voglibose is FALSE?

Accepted Answer

It can cause hypoglycemia.

Answer

It acts by inhibiting the enzyme alpha-glucosidase.

Answer

It reduces post-prandial hyperglycemia.

Answer

It decreases the progression of impaired glucose tolerance to overt diabetes mellitus.

Question 6

Which of the following group of antidiabetic drugs are contraindicated in patients with Multiple Endocrine Neoplasia (MEN) syndrome?

Accepted Answer

GLP-1 analogues

Answer

Biguanides

Answer

Alpha-glucosidase inhibitors

Answer

Meglitinides

Question 7

Which of the following characteristics makes metformin a preferred biguanide compared to phenformin?

Accepted Answer

It is less liable to cause lactic acidosis

Answer

It is more potent

Answer

It does not interfere with vitamin B12 absorption

Answer

It is not contraindicated in patients with kidney disease

Question 8

Which drug's action requires the presence of insulin to produce its therapeutic effect?

Accepted Answer

Pioglitazone

Answer

Glibenclamide

Answer

Nateglinide

Answer

Empagliflozin

Question 9

A patient diagnosed with a brain tumor is to be treated with steroids to decrease cerebral edema. Which type of steroid is preferred and why?

Accepted Answer

The preferred steroids cause less sodium and water retention.

Answer

The preferred steroids are more potent.

Answer

The preferred steroids can be administered intravenously.

Answer

The preferred steroids inhibit brain tumors directly.

Question 10

All of the following drugs can be used in the treatment of postmenopausal osteoporosis EXCEPT:

Accepted Answer

Thyroxine

Answer

Alendronate

Answer

Teriparatide

Answer

Calcium

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?